Early safety indicators of COVID-19 convalescent plasma in 5000 patients

BACKGROUND: Convalescent plasma is the only antibody-based therapy currently available for patients with coronavirus disease 2019 (COVID-19). It has robust historical precedence and sound biological plausibility. Although promising, convalescent plasma has not yet been shown to be safe as a treatmen...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:J Clin Invest
Autores principales: Joyner, Michael J., Wright, R. Scott, Fairweather, DeLisa, Senefeld, Jonathon W., Bruno, Katelyn A., Klassen, Stephen A., Carter, Rickey E., Klompas, Allan M., Wiggins, Chad C., Shepherd, John R.A., Rea, Robert F., Whelan, Emily R., Clayburn, Andrew J., Spiegel, Matthew R., Johnson, Patrick W., Lesser, Elizabeth R., Baker, Sarah E., Larson, Kathryn F., Ripoll, Juan G., Andersen, Kylie J., Hodge, David O., Kunze, Katie L., Buras, Matthew R., Vogt, Matthew N.P., Herasevich, Vitaly, Dennis, Joshua J., Regimbal, Riley J., Bauer, Philippe R., Blair, Janis E., Van Buskirk, Camille M., Winters, Jeffrey L., Stubbs, James R., Paneth, Nigel S., Verdun, Nicole C., Marks, Peter, Casadevall, Arturo
Formato: Artigo
Lenguaje:Inglês
Publicado: American Society for Clinical Investigation 2020
Materias:
Clinical Medicine
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7456238/
https://ncbi.nlm.nih.gov/pubmed/32525844
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI140200
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares